Mayne Pharma Group Limited (MYX) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the Maine Pharma Group Limited Fall Year 2026 results. All participants are in a listen-only mode. There will be a presentation followed by a question and answer session. If you would like to ask a question via the phone, you will need to press the start key followed by the number 1 on your telephone keypad. If you would like to ask a question via the webcast, please enter it into the ask a question box and click submit. I'd now like to hand the conference over to Mr. Aaron Gray, CEO. Please go ahead. Thank you, operator. Good morning, everyone, and thank you for joining Maine Pharma's fiscal year 26 full-year results presentation. I'm Aaron Gray, Chief Executive Officer, and I'm joined today by Griffin Buchanan, our Chief Financial Officer, who was appointed in August. Today, I'll begin with our fiscal 26 corporate highlights and global footprint. Griffin will then take you through the group financial performance before I return to walk through each of the three segments, Women's Health, Dermatology and DistributeRx, and International. And we'll then close with our future growth drivers and fiscal year 27 focus and outlook. Then we will open the line for questions. Please take a moment to read the disclaimer regarding forward-looking statements and the use of non-IFRS measures. Today's comments should be read in conjunction with our audited financial statements and ASX disclosures. Excuse me. Turning to slide three and our fiscal year 26 corporate highlights. Fiscal year 26 was a year of resilience and focus against a backdrop of considerable distraction and disruption. First, as part of our realignment of the Women's Health Salesforce, we refreshed our sales and marketing materials to better support the team in the field. We...